177 related articles for article (PubMed ID: 20113293)
21. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
[TBL] [Abstract][Full Text] [Related]
22. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
23. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
24. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
25. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
26. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
[TBL] [Abstract][Full Text] [Related]
27. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
28. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
Christoforidis A; Zevgaridou E; Tsatra I; Perifanis V; Vlachaki E; Papassotiriou I; Apostolakou F; Athanassiou-Metaxa M
J Pediatr Hematol Oncol; 2007 Sep; 29(9):598-601. PubMed ID: 17805032
[TBL] [Abstract][Full Text] [Related]
29. Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan.
Peng CT; Wu KH; Wu SF; Liang DC; Yang CP; Jang RC; Wang LY; Hsiao CC
Hemoglobin; 2006; 30(1):125-30. PubMed ID: 16540425
[TBL] [Abstract][Full Text] [Related]
30. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
31. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
[TBL] [Abstract][Full Text] [Related]
32. Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
Tsiapras D; Fragatou S; Farmaki K; Kyrzopoulos S; Paraskevaidis I; Voudris V; Kremastinos D
Hemoglobin; 2010 Jun; 34(3):210-20. PubMed ID: 20524811
[TBL] [Abstract][Full Text] [Related]
33. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.
Galia M; Midiri M; Bartolotta V; Morabito A; Rizzo M; Mangiagli A; Malizia R; Borsellino Z; Capra M; D'Ascola DG; Magnano C; Gerardi C; Rigano P; Maggio A;
Hemoglobin; 2003 May; 27(2):63-76. PubMed ID: 12779268
[TBL] [Abstract][Full Text] [Related]
34. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
Abdelrazik N
Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
[TBL] [Abstract][Full Text] [Related]
35. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
Mirbehbahani N; Jahazi A; Rahim Abad HH
Hematology; 2012 May; 17(3):183-6. PubMed ID: 22664119
[TBL] [Abstract][Full Text] [Related]
36. Combined oral and parenteral iron chelation in beta thalassaemia major.
Balveer K; Pyar K; Wonke B
Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
[TBL] [Abstract][Full Text] [Related]
37. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
[TBL] [Abstract][Full Text] [Related]
38. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
39. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
Aydinok Y; Ulger Z; Nart D; Terzi A; Cetiner N; Ellis G; Zimmermann A; Manz C
Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
[TBL] [Abstract][Full Text] [Related]
40. Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Peng CT; Chang JS; Wang LY; Chiou SS; Hsiao CC; Wang SC; Hung GY; Wu KH
Hemoglobin; 2009; 33(5):304-11. PubMed ID: 19814676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
